In this issue:
Dapagliflozin in HF with mildly reduced or preserved EF
Acetazolamide in acute decompensated HF with volume overload
Association of empagliflozin treatment with albuminuria in HF patients
Hyperkalaemia as a cause of MRA undertreatment in HF
Riociguat for pulmonary hypertension with HFPEF
Transvenous right greater splanchnic nerve ablation in HFPEF
Stem cell-derived extracellular vesicles reduce expression of cardiac hypertrophy molecules
Periodontal status, CRP, NTproBNP and incident HF
Alerting clinicians to 1-year mortality risk in patients hospitalised with HF
Uric acid and SGLT-2 inhibition with empagliflozin in HFREF
Please login below to download this issue (PDF)